Trials / Recruiting
RecruitingNCT07204340
TLN-372 in Advanced KRAS Mutant Solid Tumors
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Treeline Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLN-372 | Specified dose on specified days |
| DRUG | TLN-372 in combination with cetuximab | Specified dose on specified days |
| DRUG | TLN-372 in combination with pembrolizumab | Specified dose on specified days |
Timeline
- Start date
- 2025-09-29
- Primary completion
- 2031-12-03
- Completion
- 2032-04-01
- First posted
- 2025-10-02
- Last updated
- 2026-02-27
Locations
10 sites across 4 countries: United States, Australia, Canada, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07204340. Inclusion in this directory is not an endorsement.